A03 — Спазмолитики И Антихолинэргические Препараты Antispas

Total Page:16

File Type:pdf, Size:1020Kb

A03 — Спазмолитики И Антихолинэргические Препараты Antispas АТХ — справочник A03 — Спазмолитики и антихолинэргические препараты Antispas. and Anticholinergic Agents and Propulsiv A03A Синтетические спазмолитики и холиноблокаторы A03D Спазмолитики в комбинации с анальгетиками Synthetic Antispasm. and Antichol. Agents Antispasmodics In Combination With Analgesics A03B Белладонна и ее производные A03E Спазмолитики и холиноблокаторы в комбинации с Belladonna and Derivatives, Plain другими препаратами Antispasm. and Antichol. In Comb. With Other Drugs A03C Спазмолитики в комбинации с психотропными препаратами A03F Стимуляторы моторики ЖКТ Antispasmodics In Combination With Psycholeptics Propulsives A03A — Синтетические спазмолитики и холиноблокаторы Synthetic Antispasm. and Antichol. Agents A03AA Синтетические холиноблокаторы - эфиры с третичной A03AD Папаверин гидрохлорид и его производные аминогруппой Papaverine and Derivatives Synt Anticholin, Esters With Tertiary Amino Group A03AE A03AB Синтетические холиноблокаторы - четвертичные A03AX Другие синтетические холиноблокаторы аммониевые соединения Other Synthetic Anticholinergic Agents Synt Anticholinergicsquaternary Ammonium Comp. A03AC Синтетические холиноблокаторы - амиды с третичной аминогруппой Synt Antispasmodics, Amides With Tertiary Amines A03AA — Синтетические холиноблокаторы - эфиры с третичной аминогруппой Synt Anticholin, Esters With Tertiary Amino Group A03AA01 Оксифенциклимин A03AA07 Дицикловерин Oxyphencyclimine Dicycloverine A03AA03 Камилофин A03AA08 Дигексиверин Camylofin Dihexyverine A03AA04 Мебеверин A03AA09 Дифемерин Mebeverine Difemerine A03AA05 Тримебутин A03AA30 Пиперидолат Trimebutine Piperidolate A03AA06 Роциверин Rociverine A03AB — Синтетические холиноблокаторы - четвертичные аммониевые соединения Synt Anticholinergicsquaternary Ammonium Comp. A03AB01 Бензилоний бромид A03AB12 Мепензолат бромид Benzilonium Mepenzolate A03AB02 Гликопирроний бромид A03AB13 Бевоний метилсульфат Glycopyrronium Bevonium A03AB03 Оксифеноний бромид A03AB14 Пипензолат бромид Oxyphenonium Pipenzolate A03AB04 Пентиенат A03AB15 Дифенамил метилсульфат Penthienate Diphemanil A03AB05 Пропантелин бромид A03AB16 (2-Бензгидрилоксиэтил) Диэтилметиламмония йодид Propantheline (2-Benzhydryloxyethyl) Diethylmethylammonium Iodide A03AB06 Отилоний бромид A03AB17 Тиемоний йодид Otilonium bromide Tiemonium Iodide A03AB07 Метантелин бромид A03AB18 Прифиний бромид Methanthelinium Prifinium Bromide A03AB08 Тридигексетил йодид A03AB19 Тимепидий бромид Tridihexethyl Timepidium Bromide A03AB09 Изопропамид йодид A03AB20 Троспий хлорид Isopropamide Trospium A03AB10 Гексоциклий метилсульфат A03AB21 Фенпивериний бромид Hexocyclium Fenpiverinium A03AB11 Польдин метилсульфат A03AB53 Оксифеноний бромид в комбинации с другими Poldine препаратами Oxyphenonium, Combinations АТХ — справочник A03AC — Синтетические холиноблокаторы - амиды с третичной аминогруппой Synt Antispasmodics, Amides With Tertiary Amines A03AC02 Диметиламинопропионилфенотиазин A03AC05 Тиропрамид Dimethylaminopropionylphenothiazine Tiropramide A03AC04 Никофетамид Nicofetamide A03AD — Папаверин гидрохлорид и его производные Papaverine and Derivatives A03AD01 Папаверин гидрохлорид A03AD30 Моксаверин Papaverine Moxaverine A03AD02 Дротаверин A03AD51 Папаверин гидрохлорид в комбинации с другими Drotaverine препаратами Papaverine, Combinations A03AX — Другие синтетические холиноблокаторы Other Synthetic Anticholinergic Agents A03AX01 Фенпипран A03AX08 Алверин Fenpiprane Alverine A03AX02 Диизопромин A03AX09 Трепибутон Diisopromine Trepibutone A03AX03 Хлорбензоксамин A03AX10 Изометептен Chlorbenzoxamine Isometheptene A03AX04 Пинаверий бромид A03AX11 Кароверин Pinaverium Caroverine A03AX05 Феноверин A03AX30 Триметилдифенилпропиламин Fenoverine Trimethyldiphenylpropylamine A03AX06 Иданпрамин A03AX58 Алверин в комбинации с другими препаратами Idanpramine Alverine, Combinations A03AX07 Проксазол Proxazole A03B — Белладонна и ее производные Belladonna and Derivatives, Plain A03BA Алкалоиды белладонны, третичные амины A03BB Полусинтетические алкалоиды белладонны, Belladonna Alkaloids, Tertiary Amines четвертичные аммониевые соединения Belladonna Alkaloids Semisynt, Quater Ammonium Comp A03BA — Алкалоиды белладонны, третичные амины Belladonna Alkaloids, Tertiary Amines A03BA01 Атропин сульфат A03BA04 Сумма алкалолидов белладонны Atropine Belladonna Total Alkaloids A03BA03 Гиосциамин Hyoscyamine A03BB — Полусинтетические алкалоиды белладонны, четвертичные аммониевые соединения Belladonna Alkaloids Semisynt, Quater Ammonium Comp A03BB01 Гиосцина бутилбромид A03BB04 Фентоний бромид Hyoscine butylbromide Fentonium A03BB02 Атропин метонитрат A03BB05 Циметропий бромид Methylatropine Cimetropium Bromide A03BB03 Метилскополамин Methylscopolamine A03C — Спазмолитики в комбинации с психотропными препаратами Antispasmodics In Combination With Psycholeptics A03CA Синтетические холиноблокаторы в комбинации с A03CC Прочие спазмолитики в комбинации с психотропными психотропными препаратами препаратами Synthetic Anticholin.Agents In Comb.W/Psycholept Other Antispasmodics In Comb. W/Psycholep. A03CB Белладонна и ее производные в комбинации с психотропными препаратами Belladonna and Derivatives In Comb.W/Psycholep АТХ — справочник A03CA — Синтетические холиноблокаторы в комбинации с психотропными препаратами Synthetic Anticholin.Agents In Comb.W/Psycholept A03CA01 Изопропамид в комбинации с психотропными A03CA06 Бевоний метилсульфат в комбинации с психотропными препаратами препаратами Isopropamide and Psycholeptics Bevonium and Psycholeptics A03CA02 Клидиний бромид в комбинации с психотропными A03CA07 Амбутоний в комбинации с психотропными препаратами препаратами Ambutonium and Psycholeptics Clidinium and Psycholeptics A03CA08 Дифеманил метилсульфат в комбинации с психотропными A03CA03 Оксифенциклимин в комбинации с психотропными препаратами препаратами Diphemanil and Psycholeptics Oxyphencyclimine and Psycholeptics A03CA30 Эмепроний бромид в комбинации с психотропными A03CA04 Отилоний бромид в комбинации с психотропными препаратами препаратами Emepronium and Psycholeptics Otilonium Bromide and Psycholeptics A03CA34 Пропантелин бромид в комбинации с психотропными A03CA05 Гликопирроний бромид в комбинации с психотропными препаратами препаратами Propantheline and Psycholeptics Glycopyrronium and Psycholeptics A03CB — Белладонна и ее производные в комбинации с психотропными препаратами Belladonna and Derivatives In Comb.W/Psycholep A03CB01 Метилскополамин в комбинации с психотропными A03CB04 Метилгоматропин в комбинации с психотропными препаратами препаратами Methylscopolamine and Psycholeptics Methylhomatropine and Psycholeptics A03CB02 Сумма алкалоидов белладонны в комбинации с A03CB31 Гиосциамин в комбинации с психотропными психотропными препаратами препаратами Belladonna Total Alkaloids and Psycholeptics Hyoscyamine and Psycholeptics A03CB03 Атропин сульфат в комбинации с психотропными препаратами Atropine and Psycholeptics A03D — Спазмолитики в комбинации с анальгетиками Antispasmodics In Combination With Analgesics A03DA Синтетические холиноблокаторы в комбинации с A03DC Прочие спазмолитики в комбинации с анальгетиками анальгетиками Other Antispasmodics In Combination W/Analgesics Synthetic Anticholin.Agents In Comb.W/Analgesics A03DB Белладонна и ее производные в комбинации с анальгетиками Belladonna and Derivatives In Comb W/Analgesics A03DA — Синтетические холиноблокаторы в комбинации с анальгетиками Synthetic Anticholin.Agents In Comb.W/Analgesics A03DA01 Тропензилин бромид в комбинации с анальгетиками A03DA04 Циклоний бромид в комбинации с анальгетиками Tropenziline and Analgesics Ciclonium and Analgesics A03DA02 Питофенон в комбинации с анальгетиками A03DA05 Камилофин в комбинации с анальгетиками Pitofenone and Analgesics Camylofin and Analgesics A03DA03 Бевоний метилсульфат в комбинации с анальгетиками A03DA06 Троспий бромид в комбинации с анальгетиками Bevonium and Analgesics Trospium and Analgesics A03DB — Белладонна и ее производные в комбинации с анальгетиками Belladonna and Derivatives In Comb W/Analgesics A03DB04 Бутилскополамин в комбинации с анальгетиками Butylscopolamine and Analgesics A03E — Спазмолитики и холиноблокаторы в комбинации с другими препаратами Antispasm. and Antichol. In Comb. With Other Drugs A03EA Спазмолитики, психотропные препараты и A03ED Спазмолитики в комбинации с прочими препаратами анальгетики в комбинации Antispasmodics In Combination With Other Drugs Antispasmodics, Psycholeptics, Analgesics In Comb A03F — Стимуляторы моторики ЖКТ Propulsives A03FA Стимуляторы моторики ЖКТ Propulsives АТХ — справочник A03FA — Стимуляторы моторики ЖКТ Propulsives A03FA01 Метоклопрамид A03FA04 Бромоприд Metoclopramide Bromopride A03FA02 Цизаприд A03FA05 Ализаприд Cisapride Alizapride A03FA03 Домперидон A03FA06 Клебоприд Domperidone Clebopride.
Recommended publications
  • WO 2010/015655 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 11 February 2010 (11.02.2010) WO 2010/015655 Al (51) International Patent Classification: sham Research Centre, Wimblehurst Road, Horsham C07C 233/79 (2006.01) C07D 277/42 (2006.01) West Sussex RH 12 5AB (GB). SVIRIDENKO, Lilya C07C 255/58 (2006.01) A61K 31/166 (2006.01) [GB/GB]; Novartis Horsham Research Centre, Wimble C07C 311/39 (2006.01) A61K 31/427 (2006.01) hurst Road, Horsham West Sussex RH 12 5AB (GB). C07D 213/74 (2006.01) A61K 31/44 (2006.01) (74) Agent: VOEGELI-LANGE, Regina; Novartis Pharma C07D 213/75 (2006.01) A61P 1/00 (2006.01) Ag, Patent Department, CH-4002 Basel (CH). C07D 213/84' (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/EP2009/060150 AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (22) International Filing Date: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 5 August 2009 (05.08.2009) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (25) Filing Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (30) Priority Data: SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, 08162006.4 7 August 2008 (07.08.2008) EP TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • TARIF DES DOUANES - ANNEXE 99 - I
    TARIF DES DOUANES - ANNEXE 99 - i Chapitre 99 DISPOSITIONS DE CLASSIFICATION SPÉCIALE - COMMERCIALES Notes. 1. Les dispositions du présent Chapitre ne sont pas régies par la règle de spécificité de la Règle générale interprétative 3 a). 2. Les marchandises qui peuvent être classées dans les dispositions du Chapitre 99, sont classées dans le Chapitre 98 si elles peuvent également être classées dans ce chapitre. 3. Les marchandises peuvent être classées dans un numéro tarifaire du présent Chapitre et peuvent bénéficier des taux de droits de douane du tarif de la nation la plus favorisée ou du tarif de préférence prévus au présent Chapitre qui s’appliquent à ces marchandises selon le traitement tarifaire applicable selon le pays d’origine, mais ce classement est subordonné au classement préalable de celles-ci dans un numéro tarifaire des Chapitres 1 à 97 et à l’observation des conditions prévues par les textes d’application qui leurs sont applicables. 4. Les termes utilisés dans ce Chapitre et dans les Chapitres 1 à 97 s’entendent au sens de ces derniers Chapitres. Émis 1 janvier 2018 99 - 1 TARIF DES DOUANES - ANNEXE Numéro Unité Tarif de la Tarif de préférence SS Dénomination des marchandises tarifaire de mes. N.P.F. applicable 9901.00.00 Articles et matières devant servir à la fabrication ou à la réparation des En fr. TPAC, TPMD, TPG, produits suivants devant être utilisés dans la pêche commerciale ou TÉU, TM, TMÉU, TACI, dans la récolte commerciale de plantes aquatiques : TC, TCR, TI, TN, TSL, TP, TCOL, TJ, TPA, Appâts artificiels; TNH, TKR, TCUE, TUA : En fr.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Poisons and Narcotic Drugs (Amendment) Ordinance 1988
    AUSTRALIAN CAPITAL TERRITORY Poisons and Narcotic Drugs (Amendment) Ordinance 1988 No. 96 of 1988 I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Ordinance under the Seat of Government (Administration) Act 1910. Dated 15 December 1988 N. M. STEPHEN Governor-General By His Excellency’s Command, CLYDE HOLDING Minister of State for the Arts and Territories An Ordinance to amend the Poisons and Narcotic Drugs Ordinance 1978 Short title 1. This Ordinance may be cited as the Poisons and Narcotic Drugs (Amendment) Ordinance 1988.1 Commencement 2. This Ordinance commences on such date as is fixed by the Minister by notice in the Gazette. Principal Ordinance 3. In this Ordinance, “Principal Ordinance” means the Poisons and Narcotic Drugs Ordinance 1978.2 (Ord. 79/88)—Cat. No. Authorised by the ACT Parliamentary Counsel—also accessible at www.legislation.act.gov.au 2 Poisons and Narcotic Drugs (Amendment) No. 96, 1988 Substances to which Division applies 4. Section 27B of the Principal Ordinance is amended by adding at the end the following paragraphs: “; (f) follicle stimulating hormone; (g) luteinising hormone; (h) thalidomide.”. Grant of authorisation 5. Section 27E of the Principal Ordinance is amended— (a) by omitting from paragraph (1) (a) “or cyclofenil” and substituting “, cyclofenil, follicle stimulating hormone or luteinising hormone”; (b) by omitting from paragraph (1) (b) “and”; and (c) by adding at the end of subsection (1) the following word and paragraph: “; and (d) in the case of an application that relates to thalidomide— the applicant is a specialist physician with no less than 5 years’ experience in the treatment of erythema nodosum leprosum.”.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,916,581 B2 Boyd Et Al
    USOO891 6581 B2 (12) United States Patent (10) Patent No.: US 8,916,581 B2 Boyd et al. (45) Date of Patent: *Dec. 23, 2014 (54) (S)-N-METHYLNALTREXONE 4,194,045 A 3, 1980 Adelstein 4,203,920 A 5, 1980 Diamond et al. (75) Inventors: Thomas A. Boyd, Grandview, NY (US); 4,241,066 A 12, 1980 Kobylecki et al. H OW d Wagoner,goner, Warwick,s NY (US);s 4,311,833.4,277,605 A T.1/1982 1981 NamikoshiBuyniski et etal. al. Suketu P. Sanghvi, Kendall Park, NJ 4.322,426 A 3/1982 Hermann et al. (US); Christopher Verbicky, 4.326,074 A 4, 1982 Diamond et al. Broadalbin, NY (US); Stephen 4.326,075 A 4, 1982 Diamond et al. “. s 4,377.568 A 3/1983 Chopra et al. Andruski, Clifton Park, NY (US) 4.385,078 A 5/1983 Onda et al. 4.427,676 A 1/1984 White et al. (73) Assignee: Progenics Pharmaceuticals, Inc., 4,430,327 A 2, 1984 Frederickson et al. Tarrytown, NY (US) 4,452,775 A 6/1984 Kent 4,457,907 A 7/1984 Porteret al. (*) Notice: Subject to any disclaimer, the term of this 4,462.839 A 7/1984 McGinley et al. patent is extended or adjusted under 35 4,518.4334,466,968 A 5/19858, 1984 McGinleyBernstein et al. U.S.C. 154(b) by 344 days. 4,533,739 A 8/1985 Pitzele et al. This patent is Subject to a terminal dis- 4,606,9094,556,552 A 12/19858/1986 PorterBechgaard et al.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20050181041A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0181041 A1 Goldman (43) Pub. Date: Aug. 18, 2005 (54) METHOD OF PREPARATION OF MIXED Related US. Application Data PHASE CO-CRYSTALS WITH ACTIVE AGENTS (60) Provisional application No. 60/528,232, ?led on Dec. 9, 2003. Provisional application No. 60/559,862, ?led (75) Inventor: David Goldman, Portland, CT (US) on Apr. 6, 2004. Correspondence Address: Publication Classi?cation LEYDIG VOIT & MAYER, LTD (51) Int. Cl.7 ....................... .. A61K 31/56; A61K 38/00; TWO PRUDENTIAL PLAZA, SUITE 4900 A61K 9/64 180 NORTH STETSON AVENUE (52) US. Cl. ............................ .. 424/456; 514/179; 514/2; CHICAGO, IL 60601-6780 (US) 514/221 (73) Assignee: MedCrystalForms, LLC, Hunt Valley, (57) ABSTRACT MD This invention pertains to a method of preparing mixed phase co-crystals of active agents With one or more materials (21) Appl. No.: 11/008,034 that alloWs the modi?cation of the active agent to a neW physical/crystal form With unique properties useful for the delivery of the active agent, as Well as compositions com (22) Filed: Dec. 9, 2004 prising the mixed phase co-crystals. Patent Application Publication Aug. 18, 2005 Sheet 1 0f 8 US 2005/0181041 A1 FIG. 1a 214.70°C z.m."m.n... 206.98°C n..0ao 142 OJ/g as:20m=3: -0.8 -1.0 40 90 1:10 2110 Temperture (°C) FIG. 1b 0.01 as:22“.Km: 217 095 24221.4 39Jmum/Q -0.8 35 155 255 255 Temperture (°C) Patent Application Publication Aug.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • The Role of Antispasmodics in Managing Irritable Bowel Syndrome
    DOI: https://doi.org/10.22516/25007440.309 Review articles The role of antispasmodics in managing irritable bowel syndrome Valeria Atenea Costa Barney,1* Alan Felipe Ovalle Hernández.1 1 Internal Medicine and Gastroenterology specialist Abstract in San Ignacio University Hospital, Pontificia Universidad Javeriana, Bogotá, Colombia. Although antispasmodics are the cornerstone of treating irritable bowel syndrome, there are a number of an- tispasmodic medications currently available in Colombia. Since they are frequently used to treat this disease, *Correspondence: [email protected] we consider an evaluation of them to be important. ......................................... Received: 26/10/18 Keywords Accepted: 11/02/19 Antispasmodic, irritable bowel syndrome, pinaverium bromide, otilonium bromide, Mebeverin, trimebutine. INTRODUCTION consistency. The criteria must be met for three consecutive months prior to diagnosis and symptoms must have started Irritable bowel syndrome (IBS) is one of the most fre- a minimum of six months before diagnosis. (3, 4) quent chronic gastrointestinal functional disorders. It is There are no known structural or anatomical explanations characterized by recurrent abdominal pain associated with of the pathophysiology of IBS and its exact cause remains changes in the rhythm of bowel movements with either or unknown. Nevertheless, several mechanisms have been both constipation and diarrhea. Swelling and bloating are proposed. Altered gastrointestinal motility may contribute frequent occurrences. (1) to changes in bowel habits reported by some patients, and a IBS is divided into two subtypes: predominance of cons- combination of smooth muscle spasms, visceral hypersen- tipation (20-30% of patients) and predominance of dia- sitivity and abnormalities of central pain processing may rrhea (20-30% of patients).
    [Show full text]
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al
    US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]